Molecular Templates initiated at Oppenheimer

Molecular Templates initiated with an Outperform at Oppenheimer. Oppenheimer analyst Kevin DeGeeter started Molecular Templates with an Outperform rating and $15 price target. The analyst believes Molecular’s Engineered Toxin Bodies platform offers a differentiated mechanism of action that will be attractive to pharma and drive partnerships in 2019 and 2020.
https://thefly.com/landingPageNews.php?id=2834959